logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
PrescriberPoint
HIPPA Logo
HIPPA COMPLIANT
HIPPA Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.

    • Heron Therapeutics, Inc. drugs

    FiltersReset Filters
    4 results

    • aponvie

      (APREPITANT)
      Heron Therapeutics, Inc.
      Usage: APONVIE is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. It is not studied for treating already established nausea and vomiting.

    • cinvanti

      (aprepitant)
      Heron Therapeutics, Inc.
      Usage: CINVANTI is indicated for the prevention of acute and delayed nausea and vomiting in adults undergoing highly and moderately emetogenic cancer chemotherapy, used in combination with other antiemetics and in specific dosing regimens. It is not studied for treating established nausea and vomiting.

    • sustol

      (granisetron)
      Heron Therapeutics, Inc.
      Usage: SUSTOL is indicated for the prevention of acute and delayed nausea and vomiting in adults undergoing moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) regimens, in combination with other antiemetics.

    • zynrelef

      (BUPIVACAINE and MELOXICAM)
      Heron Therapeutics, Inc.
      Usage: ZYNRELEF is indicated for postsurgical analgesia in adults for up to 72 hours following soft tissue and orthopedic surgical procedures, including foot and ankle surgeries. Its safety and efficacy have not been established in highly vascular surgeries like intrathoracic, extensive spinal, and head and neck procedures.